A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer

Journal of the Medical Association of Thailand

Volumn 96, Issue SUPPL2, 2013, Pages

  Ithimakin, Suthinee ^a   Ratanawichitrasin, Adune ^a   Veerasarn, Vutisiri ^a   Akewanlop, Charuwan ^a   Soparattanapaisarn, Nopadol ^a   Rojananin, Supakorn ^a   O charoenrat, Pornchai ^a   Prasarttong osoth, Poramaporn ^a   Srimuninnimit, Vichien ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Carboplatin; Chemotherapy; Gemcitabine; Locally advanced breast cancer; Neoadjuvant therapy

Indexed keywords

ANTIBIOTIC AGENT; AROMATASE INHIBITOR; CARBOPLATIN; GEMCITABINE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONSTIPATION; DEATH; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; MAMMOGRAPHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; RASH; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TOXICITY; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY;

EID: 84876018353     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9.
2. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000; 83: 1480-7.
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.
4. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A: 645-52.
5. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507-16.
6. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
7. Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60: 303-7.
8. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6.
9. Nagourney RA. Gemcitabine plus cisplatin in breast cancer. Oncology (Williston Park) 2001; 15: 28-33.
10. Martin M, Diaz-Rubio E, Casado A, Santabarbara P, Lopez Vega JM, Adrover E, et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992; 10: 433-7.
11. O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993; 11: 2112-7.
12. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21: 2600-8.
13. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-27.
14. Sanchez-Rovira P, Jaen A, Duenas R, Porras I, Martinez E, Medina B, et al. Neoadjuvant gemcitabine therapy for breast cancer. Clin Breast Cancer 2002; 3 Suppl 1: 39-44.
15. Hamm JT, Wilson JW, Rastogi P, Lembersky BC, Tseng GC, Song YK, et al. Gemcitabine/epirubicin/ paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer 2008; 8: 257-63.
16. Gomez H, Kahatt C, Falcon S, Santillana S, de Mendoza FH, Valdivia S, et al. A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report. Semin Oncol 2001; 28: 57-61.
17. Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, et al. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 2008; 98: 1327-35.
18. Yardley DA, Peacock NW, Dickson NR, White MB, Vazquez ER, Foust JT, et al. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer. Clin Breast Cancer 2010; 10: 217-23.
19. Yardley DA, Zubkus J, Daniel B, Inhorn R, Lane CM, Vazquez ER, et al. A phase II trial of dosedense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clin Breast Cancer 2010; 10: 367-72.
20. Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Koppiker CB, et al. A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up. Breast Cancer 2012 Feb 22. DOI:10.1007/s12282-012-0343-4.
21. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-27.
22. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010; 16: 53-61.
23. Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011; 57: 468-87.
24. Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011; 22: 848-56.
25. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81